Your browser doesn't support javascript.
loading
Prevalence of primary aldosteronism among patients with type 2 diabetes.
Tancredi, Mauro; Johannsson, Gudmundur; Eliasson, Björn; Eggertsen, Robert; Lindblad, Ulf; Dahlqvist, Sofia; Imberg, Henrik; Lind, Marcus.
Afiliação
  • Tancredi M; Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
  • Johannsson G; Department of Medicine, NU-Hospital Group, Trollhättan and Uddevalla, Sweden.
  • Eliasson B; Department of Internal Medicine and Clinical Nutrition Institute of Medicine Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Eggertsen R; Department of Endocrinology, Sahlgrenska University Hospital Gothenburg, Gothenburg, Sweden.
  • Lindblad U; Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
  • Dahlqvist S; Department of Public Health and Community Medicine, Institute of Medicine, Primary Health Care, University of Gothenburg, Gothenburg, Sweden.
  • Imberg H; Department of Public Health and Community Medicine, Institute of Medicine, Primary Health Care, University of Gothenburg, Gothenburg, Sweden.
  • Lind M; Department of Medicine, NU-Hospital Group, Trollhättan and Uddevalla, Sweden.
Clin Endocrinol (Oxf) ; 87(3): 233-241, 2017 Sep.
Article em En | MEDLINE | ID: mdl-28493291
CONTEXT: Diabetes and hypertension coexist in 40%-60% of individuals with type 2 diabetes. The coexistence of these two conditions is associated with increased risk of retinopathy, nephropathy and cardiovascular disease. OBJECTIVE: To investigate the prevalence of primary aldosteronism (PA) in a general cohort of persons with type 2 diabetes. DESIGN: Cross-sectional study involving six diabetes outpatient clinics in Sweden. PATIENTS: were enrolled individuals with type 2 diabetes between February 2008 and December 2013. MEASUREMENTS: Plasma aldosterone concentrations (PAC pmol/L) and direct renin concentrations (DRC mIU/L) were measured. Patients with increased aldosterone renin ratios (ARR) >65 were further evaluated for PA. RESULTS: Of 578 consecutively screened patients with type 2 diabetes, 27 were treated with mineralocorticoid receptor antagonists (MRA) and potassium-sparing diuretics not further evaluated. Among the remaining 551 patients, 38 had increased ARR, including 22 who were clinically indicated for PA tests and 16 who were not further evaluated due to severe comorbidities and old age. There were five (0.93%) patients with confirmed PA after computerized tomography and adrenal venous sampling. Patients with PA had higher systolic blood pressure (P=.032) and lower potassium levels (P=.027) than those without PA. No significant association was found between plasma aldosterone and diabetic complications. CONCLUSIONS: The prevalence of PA in an unselected cohort of patients with type 2 diabetes is relatively low, and measures of plasma aldosterone are not strong risk factors for micro- and macrovascular diabetic complications.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Hiperaldosteronismo Tipo de estudo: Clinical_trials / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Clin Endocrinol (Oxf) Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Suécia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Hiperaldosteronismo Tipo de estudo: Clinical_trials / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Clin Endocrinol (Oxf) Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Suécia